Volume 86 Issue 10 | pp. 56-61
Issue Date: March 10, 2008

Financial Windfall From Lyrica

Royalty payouts from university-held patents have power to transform chemistry departments
Department: Science & Technology

OF ALL THE would-be pharmaceutical agents that academic researchers study, very few turn into commercial medications. Even fewer still generate millions of dollars for the drugs' discoverers and their universities. And for a university to land a drug-related windfall at the next level up—in the billion-dollar blockbuster range—is all but unheard of. Yet Northwestern University stands to bring in that kind of wealth from its royalties on Lyrica, a pain and epilepsy medication . . .

To view the rest of this content, please log in with your ACS ID.



 

More on this Topic

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society